World's Best Scientists 2026 revealed!

D-Index & Metrics

Chemistry

D-Index
60
Citations
16160
World Ranking
9576
National Ranking
541

Biology and Biochemistry

D-Index
64
Citations
16987
World Ranking
9548
National Ranking
726

Overview

Oleg Fedorov is affiliated with the University of Oxford in the United Kingdom. Their research spans several main fields of study including Biochemistry, Genetics and Molecular Biology, Medicine, and Materials Science. These domains are further detailed into subfields such as Molecular Biology, Materials Chemistry, Infectious Diseases, Oncology, and Epidemiology.

The core scientific topics addressed by Fedorov encompass Peptidase Inhibition and Analysis, Crystallization and Solubility Studies, Ion-surface interactions and analysis, X-ray Diffraction in Crystallography, Lipid Membrane Structure and Behavior, Computational Drug Discovery Methods, and SARS-CoV-2 and COVID-19 Research.

Fedorov's publication record includes work in various reputable venues, with the most frequent being Zenodo (CERN European Organization for Nuclear Research), Science, Angewandte Chemie International Edition, BMC Infectious Diseases, and the Journal of Medicinal Chemistry.

  • Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors, 2023, Science
  • Binding-Site Purification of Actives (B-SPA) Enables Efficient Large-Scale Progression of Fragment Hits by Combining Multi-Step Array Synthesis With HT Crystallography, 2025, Angewandte Chemie International Edition
  • Antibiotic resistance and viral co-infection in children diagnosed with pneumonia caused by Mycoplasma pneumoniae admitted to Russian hospitals during October 2023-February 2024, 2025, BMC Infectious Diseases
  • Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor, 2024, Journal of Medicinal Chemistry
  • High-throughput crystallography for rapid early-stage fragment growth from crude arrays by low-cost robotics, 2023, Zenodo (CERN European Organization for Nuclear Research)

Frequent collaborators include L. Koekemoer, F. von Delft, James M. Bennett, T. Krojer, and Harold Grosjean, with multiple co-authored publications.

Best Publications

  • Selective inhibition of BET bromodomains.

    Panagis Filippakopoulos;Jun Qi;Sarah Picaud;Yao Shen

  • Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination.

    Masoud Vedadi;Frank H. Niesen;Abdellah Allali-Hassani;Oleg Y. Fedorov

  • RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.

    Sarah Picaud;Christopher Wells;Ildiko Felletar;Deborah Brotherton

  • A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases

    Oleg Fedorov;Brian Marsden;Vanda Pogacic;Peter Rellos

  • Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

    Pietro Ciceri;Susanne Müller;Alison O'Mahony;Oleg Fedorov

  • The (un)targeted cancer kinome

    Oleg Fedorov;Susanne Müller;Stefan Knapp;Stefan Knapp

  • Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains

    Duncan A Hay;Oleg Fedorov;Sarah Martin;Dean C Singleton

  • Rapid covalent-probe discovery by electrophile fragment screening

    Efrat Resnick;Anthony Bradley;Jinrui Gan;Alice Douangamath

  • PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains

    Sarah Picaud;David Da Costa;Angeliki Thanasopoulou;Panagis Filippakopoulos

  • CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

    Ariane Hammitzsch;Cynthia Tallant;Oleg Fedorov;Alison O’Mahony

  • 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.

    David S. Hewings;Minghua Wang;Martin Philpott;Oleg Fedorov

  • Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.

    Sarah Picaud;Sarah Picaud;Oleg Fedorov;Oleg Fedorov;Angeliki Thanasopoulou;Katharina Leonards

  • Structural diversity in the RGS domain and its interaction with heterotrimeric G protein alpha-subunits.

    Meera Soundararajan;Francis S. Willard;Adam J. Kimple;Andrew P. Turnbull

  • Specific Clk Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing.

    Oleg Fedorov;Kilian Huber;Andreas Eisenreich;Panagis Filippakopoulos

  • Structural Analysis Identifies Imidazo[1,2-b]Pyridazines as PIM Kinase Inhibitors with In vitro Antileukemic Activity

    Vanda Pogacic;Alex N. Bullock;Oleg Fedorov;Panagis Filippakopoulos

  • Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor

    Laetitia J. Martin;Manfred Koegl;Gerd Bader;Xiao-Ling Cockcroft

  • Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase

    Alex N. Bullock;Judit E. Debreczeni;Oleg Y. Fedorov;Adam Nelson

  • A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain

    Oakley B. Cox;Oakley B. Cox;Tobias Krojer;Patrick Collins;Octovia Monteiro;Octovia Monteiro

  • Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking.

    Marion Schuller;Galen J. Correy;Stefan Gahbauer;Daren Fearon

  • LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor

    Peter G. K. Clark;Lucas C. C. Vieira;Cynthia Tallant;Oleg Fedorov

  • Kinase Inhibitor Selectivity Profiling Using Differential Scanning Fluorimetry

    Oleg Fedorov;Frank H. Niesen;Stefan Knapp

  • Abstract 5387: Dual kinase/bromodomain inhibitors for rationally designed polypharmacology

    Elizabeth R. Quinn;Pietro Ciceri;Susanne Müller-Knapp;Alison O'Mahony

Frequent Co-Authors

Stefan Knapp
Stefan Knapp Goethe University Frankfurt
Cheryl H. Arrowsmith
Cheryl H. Arrowsmith Structural Genomics Consortium
Aled M. Edwards
Aled M. Edwards Structural Genomics Consortium
Panagis Filippakopoulos
Panagis Filippakopoulos Structural Genomics Consortium
Paul Brennan
Paul Brennan International Agency For Research On Cancer
Susanne Müller
Susanne Müller Structural Genomics Consortium
Alex N. Bullock
Alex N. Bullock University of Oxford
Opher Gileadi
Opher Gileadi Karolinska Institute
Udo Oppermann
Udo Oppermann University of Oxford
Masoud Vedadi
Masoud Vedadi Structural Genomics Consortium

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Chemistry in the USA opens doors to a variety of related online degrees and career paths that complement the core discipline. For those interested in the legal side of science, pursuing an online associates in criminal justice can provide foundational knowledge helpful in forensic chemistry roles.

Understanding the cost of criminal justice degree programs is vital when planning your education, as budgeting for tuition and fees will impact your long-term academic strategy.

Similarly, degrees like the paralegal associate degree can provide entry points into regulatory and compliance roles within pharmaceutical companies or chemical manufacturing firms.

For those aiming to blend chemistry knowledge with business skills, becoming a pharmaceutical sales representative is a lucrative option. Reviewing the drug rep salary and career pathways can give practical insight into this industry.

Overall, linking chemistry with these complementary degrees can broaden career opportunities and enhance the value of your scientific expertise.

Best Scientists Citing Oleg Fedorov

Trending Scientists